McEnany Patrick J's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 24, 2021
- Accession no.
- 0001161697-21-000406
- Filed
- Aug 24, 2021
- Trade date
- Aug 20-23, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $764.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McEnany Patrick JCIK 0000929985 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2021 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +80,000 | $3.12 | +$249,600 | 4,928,304 | Direct | |
| Aug 20, 2021 | Common stock, par value $0.001 per share | SSaleDisposed | −54,161 | $5.52F1,F2 | −$298,968.72 | 4,874,143 | Direct | |
| Aug 23, 2021 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +120,000 | $3.12 | +$374,400 | 4,994,143 | Direct | |
| Aug 23, 2021 | Common stock, par value $0.001 per share | SSaleDisposed | −82,617 | $5.63F1,F3 | −$465,133.71 | 4,911,526 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2021 | Common Stock | MOption exerciseDisposed | −80,000 | $0.00 | $0 | 3,371,667 | Direct | |
| Aug 23, 2021 | Common Stock | MOption exerciseDisposed | −120,000 | $0.00 | $0 | 3,251,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold to cover exercise price of options and tax withholding requirements.
Referenced by the price of 2 transactions in Table I.
- F2
Shares were sold in various lots from $5.455 to $5.601 per share. The listed sale price represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.
- F3
Shares were sold in various lots from $5.59 to $5.675 per share. The listed sale price represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.